The companies used Sutro Biopharma’s proprietary cell-free expression technology on a commercial scale to manufacture Sutro’s luvelta, an antibody-drug conjugate.
With China aggressively pursuing a strategy to become the world’s leader in biotech, America must invest in biomanufacturing to maintain its global dominance.
The week’s biggest announcement was WuXi AppTec’s sale of WuXi Advanced Therapies, its cell and gene therapy unit, to U.S.-based private equity firm Altaris.
The acquisition, which took the global contract development and manufacturing organization private, is a one-off the likes of which the industry will not see again.
The proposed legislation, which prevents U.S. federal funds from supporting certain Chinese contract manufacturers, was omitted from a defense bill leaving its fate in limbo.
This week, drug manufacturers — including Amgen, Eli Lilly, Novo Nordisk and Sanofi — announced plans to expand their production footprints in the U.S., Europe and Asia.
